Advertisement

Role of Topical Therapy: Imiquimod

  • Elise Ng
  • Vicki LevineEmail author
Chapter

Abstract

The gold standard for treatment of lentigo maligna is complete surgical excision. Second-line non-surgical modalities include radiotherapy, laser therapy, and topical therapies. Evidence for the use of various topical agents, including tretinoin, azelaic acid, and 5-fluorouracil, is limited. The greatest evidence exists for imiquimod 5 % cream, which has been investigated in multiple case series and studies. Topical imiquimod appears to be effective in a subset of cases, but clinical response is unpredictable and guidelines for monitoring and follow-up remain to be established. As such, its role in the treatment of lentigo maligna remains controversial and additional studies with higher quality evidence are needed.

Keywords

Imiquimod Lentigo maligna Melanoma in-situ Melanoma Topical immunomodulator Immune response modifier 

References

  1. 1.
    Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143(4):843–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Micali G, Lacarrubba F, Nasca MR, Schwartz RA. Topical pharmacotherapy for skin cancer: part I. Pharmacology. J Am Acad Dermatol. 2014;70(6):965.e1–12, quiz 977–8.CrossRefGoogle Scholar
  3. 3.
    Wolf IH, Kodama K, Cerroni L, Kerl H. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol. 2007;29(3):237–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol. 2006;155(4):653–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Schon M, Schon MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem. 2007;14(6):681–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Schon MP, Schon M. The small-molecule immune response modifier imiquimod – its mode of action and clinical use in the treatment of skin cancer. Expert Opin Ther Targets. 2006;10(1):69–76.CrossRefPubMedGoogle Scholar
  7. 7.
    Schon MP, Schon M. Imiquimod: mode of action. Br J Dermatol. 2007;157 Suppl 2:8–13.CrossRefPubMedGoogle Scholar
  8. 8.
    Michalopoulos P, Yawalkar N, Bronnimann M, Kappeler A, Braathen LR. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004;151(4):903–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Bong AB, Bonnekoh B, Franke I, Schon M, Ulrich J, Gollnick H. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology. 2002;205(2):135–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg. 2008;34(2):147–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH. A pilot study of treatment of lentigo maligna with 5 % imiquimod cream. Br J Dermatol. 2004;151(2):485–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Kirtschig G, van Meurs T, van Doorn R. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate. Acta Derm Venereol. 2015;95(1):83–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Ly L, Kelly JW, O'Keefe R, et al. Efficacy of imiquimod cream, 5 %, for lentigo maligna after complete excision: a study of 43 patients. Arch Dermatol. 2011;147(10):1191–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149 Suppl 66:66–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 2009;160(5):994–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol. 2004;29(1):15–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Spenny ML, Walford J, Werchniak AE, et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5 %: 12 case reports. Cutis. 2007;79(2):149–52.PubMedGoogle Scholar
  18. 18.
    Van Meurs T, Van Doorn R, Kirtschig G. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients. Dermatol Surg. 2010;36(6):853–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol. 2005;141(4):510–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Wong JG, Toole JW, Demers AA, Musto G, Wiseman MC. Topical 5 % imiquimod in the treatment of lentigo maligna. J Cutan Med Surg. 2012;16(4):245–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol. 2015;73(2):205–12.CrossRefPubMedGoogle Scholar
  22. 22.
    Read T, Noonan C, David M, et al. A systematic review of non-surgical treatments for lentigo maligna. J Eur Acad Dermatol Venereol. 2015.Google Scholar
  23. 23.
    McLeod M, Choudhary S, Giannakakis G, Nouri K. Surgical treatments for lentigo maligna: a review. Dermatol Surg. 2011;37(9):1210–28.CrossRefPubMedGoogle Scholar
  24. 24.
    Hou JL, Reed KB, Knudson RM, et al. Five-year outcomes of wide excision and Mohs micrographic surgery for primary lentigo maligna in an academic practice cohort. Dermatol Surg. 2015;41(2):211–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Gautschi M, Oberholzer PA, Baumgartner M, Gadaldi K, Yawalkar N, Hunger RE. Prognostic markers in lentigo maligna patients treated with imiquimod cream: a long-term follow-up study. J Am Acad Dermatol. 2016;74(1):81–7. e81.CrossRefPubMedGoogle Scholar
  26. 26.
    Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM. A randomized trial of the off-label use of imiquimod, 5 %, cream with vs without tazarotene, 0.1 %, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol. 2012;148(5):592–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5 % cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type. J Am Acad Dermatol. 2015;72(6):1047–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Paraskevas LR, Halpern AC, Marghoob AA. Utility of the Wood's light: five cases from a pigmented lesion clinic. Br J Dermatol. 2005;152(5):1039–44.CrossRefPubMedGoogle Scholar
  29. 29.
    Schiffner R, Schiffner-Rohe J, Vogt T, et al. Improvement of early recognition of lentigo maligna using dermatoscopy. J Am Acad Dermatol. 2000;42(1 Pt 1):25–32.CrossRefPubMedGoogle Scholar
  30. 30.
    de Troya-Martin M, Frieyro-Elicegui M, Funez Liebana R, Aguilar Bernier M, Fernandez-Canedo NI, Blazquez Sanchez N. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases. Dermatol Surg. 2008;34(11):1561–6.PubMedGoogle Scholar
  31. 31.
    Guitera P, Haydu LE, Menzies SW, et al. Surveillance for treatment failure of lentigo maligna with dermoscopy and in vivo confocal microscopy: new descriptors. Br J Dermatol. 2014;170(6):1305–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Alarcon I, Carrera C, Alos L, Palou J, Malvehy J, Puig S. In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod. J Am Acad Dermatol. 2014;71(1):49–55.CrossRefPubMedGoogle Scholar
  33. 33.
    Alarcon I, Carrera C, Puig S, Malvehy J. Clinical usefulness of reflectance confocal microscopy in the management of facial lentigo maligna melanoma. Actas Dermosifiliogr. 2014;105(3):e13–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Guitera P, Moloney FJ, Menzies SW, et al. Improving management and patient care in lentigo maligna by mapping with in vivo confocal microscopy. JAMA Dermatol. 2013;149(6):692–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Guitera P, Pellacani G, Crotty KA, et al. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. J Invest Dermatol. 2010;130(8):2080–91.CrossRefPubMedGoogle Scholar
  36. 36.
    Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5 % imiquimod cream complicated by the development of invasive disease. Arch Dermatol. 2003;139(7):945–7.CrossRefPubMedGoogle Scholar
  37. 37.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol. 2008;58(1):142–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Abdelmalek M, Loosemore MP, Hurt MA, Hruza G. Geometric staged excision for the treatment of lentigo maligna and lentigo maligna melanoma: a long-term experience with literature review. Arch Dermatol. 2012;148(5):599–604.CrossRefPubMedGoogle Scholar
  40. 40.
    Iorizzo 3rd LJ, Chocron I, Lumbang W, Stasko T. Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in situ. Dermatol Surg. 2013;39(3 Pt 1):365–71.CrossRefPubMedGoogle Scholar
  41. 41.
    Martires KJ, Capaldi L, Pattee SF, Maloney ME, Bordeaux JS. Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. Arch Dermatol. 2010;146(9):1047–8.CrossRefPubMedGoogle Scholar
  42. 42.
    Kaidbey K, Owens M, Liberda M, Smith M. Safety studies of topical imiquimod 5 % cream on normal skin exposed to ultraviolet radiation. Toxicology. 2002;178(2):175–82.CrossRefPubMedGoogle Scholar
  43. 43.
    Tran H, Moreno G, Shumack S. Imiquimod as a dermatological therapy. Expert Opin Pharmacother. 2004;5(2):427–38.CrossRefPubMedGoogle Scholar
  44. 44.
    Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z. Interventions for melanoma in situ, including lentigo maligna. Cochrane Database Syst Rev. 2014;12, CD010308.Google Scholar
  45. 45.
    Kai AC, Richards T, Coleman A, Mallipeddi R, Barlow R, Craythorne EE. Five-year recurrence rate of lentigo maligna after treatment with imiquimod. Br J Dermatol. 2016;174(1):165–8.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.The Ronald O. Perelman Department of DermatologyNew York University School of MedicineNew YorkUSA
  2. 2.Department of DermatologyNYU/LangoneNew YorkUSA

Personalised recommendations